WO2026110119 - DOUBLE STRANDED RNAI AGENTS, COMPOSITIONS AND METHODS OF USE
National phase entry is expected:
Publication Number
WO/2026/110119
Publication Date
28.05.2026
International Application No.
PCT/IB2025/062012
International Filing Date
24.11.2025
Title **
[English]
DOUBLE STRANDED RNAI AGENTS, COMPOSITIONS AND METHODS OF USE
[French]
AGENTS D'ARNI DOUBLE BRIN, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
Applicants **
NOVARTIS AG
Inventors
HAEMMIG, Stefan
HAGEN, Caitlin Jeanette
HUNZIKER, Juerg
TAN, Ge
TRAUGER, John Wesley
WEILER, Jan
Priority Data
63/724,671
25.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7756 | |
| EPO | Filing, Examination, Granting | 74576 | |
| Japan | Filing, Examination, Granting | 4131 | |
| South Korea | Filing, Examination, Granting | 6095 | |
| USA | Filing, Examination, Granting | 28690 |
Total:
121,248
Contact Us
Abstract[English]
Disclosed are, inter alia, double stranded RNAi (dsRNAi) agents inhibiting expression of proprotein convertase subtilisin kexin 9 (PCSK9), for example, human PCSK9, compositions including the same, and methods of treatment using the same.[French]
L'invention concerne, entre autres, des agents d'ARNi double brin (dsRNAi) inhibant l'expression de la proprotéine convertase subtilisine kexine 9 (PCSK9), par exemple, PCSK9 humain, des compositions les comprenant, et des procédés de traitement les utilisant.